Licensed provider care
Online clinical evaluation and ongoing access to a care team when you have treatment questions.
Four weekly doses in one pen, if prescribed
Zepbound® KwikPen access through online weight care
Complete an online clinical evaluation for the multi-dose Zepbound KwikPen, with self-pay fulfillment and continuing provider support when appropriate.
- Average weight loss of about 20% in manufacturer trials at the studied dose
- One multi-dose pen contains four weekly doses
- Self-pay access with direct-to-home fulfillment, if prescribed
The clinical assessment does not guarantee eligibility, treatment, a prescription, coverage, or medication availability.
Weekly multi-dose GLP-1/GIP injection
tirzepatideZepbound® KwikPen
About the medication
What is the Zepbound KwikPen?
Zepbound contains tirzepatide, a medicine that acts on GLP-1 and GIP pathways involved in appetite and metabolic regulation.
The KwikPen is a multi-dose device containing four doses of one strength. It is used once weekly with a separate compatible needle and only according to the supplied instructions.
How it compares
A multi-dose version of Zepbound
- 01
The KwikPen holds four weekly doses rather than one single-use dose.
- 02
The medicine and available strengths are the same as other Zepbound presentations.
- 03
The reference KwikPen pathway is self-pay; insurance-based Zepbound access may use a different presentation and pharmacy.
Access and pricing
Know the path before you decide
Your provider first determines whether prescription treatment is appropriate. You can then review the relevant access option before moving forward.
Self-pay only
First month$299
Ongoing range$399–$449/mo
Reference pricing depends on dose and manufacturer offers. Medication and membership charges are separate.
Start with a clinical assessmentCheck insurance options for weight careImportant safety information
Prescription GLP-1 treatment is not appropriate for everyone
Tirzepatide can cause serious side effects and is not appropriate for everyone. Review the official prescribing information with a licensed clinician.
Explore potential results
What could about 20% over the studied period look like for you?
Adjust the slider to see a simple illustration using the published study average. It is not a prediction or guarantee.
Illustration based on manufacturer research of tirzepatide in adults with obesity or overweight plus a related condition, alongside diet and exercise. Individual results vary.
Study-average illustration−50 lb
From 252 lb to about 202 lb
Based on a 20% average; individual results vary.The MOVA care journey
From online assessment to ongoing support
One connected process helps you understand each clinical, access, and fulfillment step.
- 01
Tell us about your health
Complete a secure online assessment about your medical history, goals, and previous weight-care experience.
- 02
Get a licensed-provider review
A licensed healthcare provider reviews your information and may ask follow-up questions before discussing treatment.
- 03
Review your options
If treatment is appropriate, review the provider's recommendation, access path, and total costs before deciding.
- 04
Arrange fulfillment
When prescribed, medication may be delivered or sent to a participating pharmacy, depending on the selected access path.
- 05
Keep your care connected
Check in with your care team for dose guidance, progress tracking, side-effect support, and ongoing clinical review.
MOVA Weight Care
Medication is one part of connected care
If treatment is appropriate, membership keeps clinical support, progress review, and access guidance in one online experience.
Begin your assessmentTreatment support
Guidance for using medication as prescribed, managing common side effects, and building sustainable habits.
Progress check-ins
Regular opportunities to share progress so your provider can review how your care plan is working.
Access guidance
Clear information about self-pay and insurance pathways that may apply to an appropriate prescription.
Using this medication
How is the Zepbound KwikPen used?
If prescribed, a dose is injected under the skin once each week. The multi-dose device requires a new compatible needle for every injection and must be used, stored, and discarded exactly as instructed.
Never change a dose or medication schedule without instructions from the prescribing healthcare professional.
Common side effects
What you may want to discuss with a provider
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Stomach pain
- Injection-site reactions
This is not a complete list. Some reactions can be serious; see the important safety information below.
Ready for the next step?
Find out whether online weight care may be right for you
Meet the care team
Expertise behind a more connected care experience
Explore the clinical leadership and public advisor profiles represented in the MOVA experience, and learn how their areas of expertise can inform thoughtful weight-care education.
An online assessment is reviewed by an appropriately licensed provider; it does not guarantee access to a particular clinician or advisor.
Meet the advisors
Frequently asked questions
Questions about Zepbound® KwikPen
How many doses are in one KwikPen?
Each KwikPen contains four weekly doses of the same strength, representing approximately one month of treatment.
Is the KwikPen covered by insurance?
The reference KwikPen path is self-pay. A provider or coverage team can explain other Zepbound presentations when insurance is being used.
Are needles included?
Compatible pen needles are separate and require appropriate prescribing and fulfillment. Follow the instructions provided with the device.
Does the assessment guarantee Zepbound?
No. A provider determines whether treatment is appropriate. A specific prescription, price, coverage, or availability is never guaranteed.
Important safety information
Know the risks before treatment
Tirzepatide can cause serious side effects and is not appropriate for everyone. Review the official prescribing information with a licensed clinician.
- Do not use with a personal or family history of medullary thyroid carcinoma or with MEN 2.
- Do not use during pregnancy; tell your provider about pregnancy plans and all current medicines.
- Do not combine with another tirzepatide medicine or another GLP-1 medicine unless specifically directed by a qualified prescriber.
- Seek medical help for severe abdominal pain, serious allergic symptoms, dehydration, or other urgent reactions.
This overview does not replace the complete prescribing information or advice from a licensed healthcare professional. Tell your provider about your health conditions, allergies, and every medicine or supplement you use.